OASIS and PIONEER PLUS support high-dose oral semaglutideBusko, MarleneCardiology News
Outcomes (glycated haemoglobin [HbA1c ] and body weight reduction, plus other relevant efficacy and safety endpoints) were tested against both placebo and active standard-of-care medications. A separate trial evaluated the cardiovascular safety of oral semaglutide in patients with T2D at high ...
At EoS, 65.1% achieved HbA1c<7%; 25.5% and 19.1% reached HbA1creduction≥1%-point plus≥3% and≥5% reduction in BW, respectively. DTSQ status improved significantly at EoS (estimated change+5.24; 95% CI, 5.24 to 6.61,p<0.0001). Of participants who remained on oral semaglutide at EoS, ...
Introduction: In this phase 4, multicentre, prospective, non-interventional PIONEER REAL Netherlands study, we assessed clinical outcomes associated with once-daily oral semaglutide use in real-world clinical practice in adults living with type 2 diabetes (T2D) nave to injectable glucose-lowering ...